Core Viewpoint - Rhein Biotech is undergoing a change in control, with Guangzhou Defu Nutrition becoming the new controlling shareholder, effective from December 24, following a series of agreements signed on December 22 [1][2]. Shareholding Structure - Prior to the agreement, Qin Benjun held 36.59% of Rhein Biotech's shares and 36.59% of the voting rights. After the transfer, he will hold 28.50% of the shares and 4.14% of the voting rights [2][3]. - Guangzhou Defu Nutrition will acquire 8.09% of Rhein Biotech's shares and 11.17% of the voting rights post-transaction [3]. Financial Details of the Transaction - The total transaction price for the share transfer is 646 million yuan (including tax), with a transfer price of 10.76 yuan per share, representing a premium of 23.68% over the closing price of 8.70 yuan on December 9 [1]. Company Background and Strategy - Guangzhou Defu Nutrition was established on December 2, 2025, and is controlled by Hou Ming and Li Zhenfu. It focuses on the healthcare and consumer sectors [4]. - Rhein Biotech aims to leverage Defu Capital's resources in the healthcare sector to enhance its operational efficiency and governance structure [4]. Expansion Plans - Rhein Biotech plans to expand its industry chain through acquisitions, specifically by purchasing 80% of Beijing Jinkangpu Food Technology Co., Ltd. [6]. - The company intends to create a closed-loop industry chain from raw materials to formulation solutions, enhancing synergy with Beijing Jinkangpu, a leading supplier of nutritional fortifiers [6]. Financial Performance - As of September 30, 2025, Rhein Biotech reported total assets of 4.985 billion yuan and net assets of 3.162 billion yuan [7]. - The company's net profit for the first three quarters of 2025 was approximately 70.40 million yuan [10].